Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole

G. N. Hortobagyi, J. U. Gutterman, G. R. Blumenschein, H. Y. Yap, A. U. Buzdar, C. K. Tashima, M. A. Burgess, Evan M Hersh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

One hundred and fourteen evaluable patients with metastatic breast cancer were treated with a program consisting of 5-FU, Adriamycin, cyclophosphamide (FAC) and nonspecific immunotherapy with Levamisole. The results of this treatment program were compared to those observed with FAC and Bacillus Calmette Guerin (BCG) and FAC chemotherapy alone, both groups treated prior to the study reported in this paper. The overall response rates and complete response rates for all three treatment regimens were identical. The duration of remission, survival of all patients and survival of responders was similar for both chemoimmunotherapy regimens, being superior to the FAC chemotherapy alone group. Immunotherapy with Levamisole was well tolerated and side-effects were experienced by less than one-fourth of the patients. Overall, Levamisole was better tolerated than BCG and was easier to administer than the latter drug. These results suggest that nonspecific immunotherapy with Levamisole might prolong remission and survival of patients with metastatic breast cancer. Since the results achieved with BCG and Levamisole appear similar, the therapeutic ratio favors the use of Levamisole.

Original languageEnglish (US)
Pages (from-to)1112-1122
Number of pages11
JournalCancer
Volume43
Issue number3
DOIs
StatePublished - 1979
Externally publishedYes

Fingerprint

Levamisole
Mycobacterium bovis
Breast Neoplasms
Fluorouracil
Doxorubicin
Cyclophosphamide
Immunotherapy
Survival
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hortobagyi, G. N., Gutterman, J. U., Blumenschein, G. R., Yap, H. Y., Buzdar, A. U., Tashima, C. K., ... Hersh, E. M. (1979). Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole. Cancer, 43(3), 1112-1122. https://doi.org/10.1002/1097-0142(197903)43:3<1112::AID-CNCR2820430350>3.0.CO;2-M

Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole. / Hortobagyi, G. N.; Gutterman, J. U.; Blumenschein, G. R.; Yap, H. Y.; Buzdar, A. U.; Tashima, C. K.; Burgess, M. A.; Hersh, Evan M.

In: Cancer, Vol. 43, No. 3, 1979, p. 1112-1122.

Research output: Contribution to journalArticle

Hortobagyi, GN, Gutterman, JU, Blumenschein, GR, Yap, HY, Buzdar, AU, Tashima, CK, Burgess, MA & Hersh, EM 1979, 'Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole', Cancer, vol. 43, no. 3, pp. 1112-1122. https://doi.org/10.1002/1097-0142(197903)43:3<1112::AID-CNCR2820430350>3.0.CO;2-M
Hortobagyi, G. N. ; Gutterman, J. U. ; Blumenschein, G. R. ; Yap, H. Y. ; Buzdar, A. U. ; Tashima, C. K. ; Burgess, M. A. ; Hersh, Evan M. / Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole. In: Cancer. 1979 ; Vol. 43, No. 3. pp. 1112-1122.
@article{d8146c563fdf4108b5dfdefd00f97ad4,
title = "Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole",
abstract = "One hundred and fourteen evaluable patients with metastatic breast cancer were treated with a program consisting of 5-FU, Adriamycin, cyclophosphamide (FAC) and nonspecific immunotherapy with Levamisole. The results of this treatment program were compared to those observed with FAC and Bacillus Calmette Guerin (BCG) and FAC chemotherapy alone, both groups treated prior to the study reported in this paper. The overall response rates and complete response rates for all three treatment regimens were identical. The duration of remission, survival of all patients and survival of responders was similar for both chemoimmunotherapy regimens, being superior to the FAC chemotherapy alone group. Immunotherapy with Levamisole was well tolerated and side-effects were experienced by less than one-fourth of the patients. Overall, Levamisole was better tolerated than BCG and was easier to administer than the latter drug. These results suggest that nonspecific immunotherapy with Levamisole might prolong remission and survival of patients with metastatic breast cancer. Since the results achieved with BCG and Levamisole appear similar, the therapeutic ratio favors the use of Levamisole.",
author = "Hortobagyi, {G. N.} and Gutterman, {J. U.} and Blumenschein, {G. R.} and Yap, {H. Y.} and Buzdar, {A. U.} and Tashima, {C. K.} and Burgess, {M. A.} and Hersh, {Evan M}",
year = "1979",
doi = "10.1002/1097-0142(197903)43:3<1112::AID-CNCR2820430350>3.0.CO;2-M",
language = "English (US)",
volume = "43",
pages = "1112--1122",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole

AU - Hortobagyi, G. N.

AU - Gutterman, J. U.

AU - Blumenschein, G. R.

AU - Yap, H. Y.

AU - Buzdar, A. U.

AU - Tashima, C. K.

AU - Burgess, M. A.

AU - Hersh, Evan M

PY - 1979

Y1 - 1979

N2 - One hundred and fourteen evaluable patients with metastatic breast cancer were treated with a program consisting of 5-FU, Adriamycin, cyclophosphamide (FAC) and nonspecific immunotherapy with Levamisole. The results of this treatment program were compared to those observed with FAC and Bacillus Calmette Guerin (BCG) and FAC chemotherapy alone, both groups treated prior to the study reported in this paper. The overall response rates and complete response rates for all three treatment regimens were identical. The duration of remission, survival of all patients and survival of responders was similar for both chemoimmunotherapy regimens, being superior to the FAC chemotherapy alone group. Immunotherapy with Levamisole was well tolerated and side-effects were experienced by less than one-fourth of the patients. Overall, Levamisole was better tolerated than BCG and was easier to administer than the latter drug. These results suggest that nonspecific immunotherapy with Levamisole might prolong remission and survival of patients with metastatic breast cancer. Since the results achieved with BCG and Levamisole appear similar, the therapeutic ratio favors the use of Levamisole.

AB - One hundred and fourteen evaluable patients with metastatic breast cancer were treated with a program consisting of 5-FU, Adriamycin, cyclophosphamide (FAC) and nonspecific immunotherapy with Levamisole. The results of this treatment program were compared to those observed with FAC and Bacillus Calmette Guerin (BCG) and FAC chemotherapy alone, both groups treated prior to the study reported in this paper. The overall response rates and complete response rates for all three treatment regimens were identical. The duration of remission, survival of all patients and survival of responders was similar for both chemoimmunotherapy regimens, being superior to the FAC chemotherapy alone group. Immunotherapy with Levamisole was well tolerated and side-effects were experienced by less than one-fourth of the patients. Overall, Levamisole was better tolerated than BCG and was easier to administer than the latter drug. These results suggest that nonspecific immunotherapy with Levamisole might prolong remission and survival of patients with metastatic breast cancer. Since the results achieved with BCG and Levamisole appear similar, the therapeutic ratio favors the use of Levamisole.

UR - http://www.scopus.com/inward/record.url?scp=0018759636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018759636&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197903)43:3<1112::AID-CNCR2820430350>3.0.CO;2-M

DO - 10.1002/1097-0142(197903)43:3<1112::AID-CNCR2820430350>3.0.CO;2-M

M3 - Article

C2 - 427716

AN - SCOPUS:0018759636

VL - 43

SP - 1112

EP - 1122

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -